This page is intended for UK healthcare professionals and other relevant decision makers only. If you are a member of the public, please click here.
This portal is funded and owned by Novartis Pharmaceuticals UK Ltd and includes content approved by Novartis.
Adverse events reporting information can be found in the footer of this page.
Indications:1
Xolair is indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU) in adult and adolescent (12 years and above) patients with inadequate response to H1 antihistamine treatment.
The recommended dose of Xolair in patients with chronic spontaneous urticaria is 300 mg by subcutaneous injection every four weeks.1
Please refer to the Xolair Summary of Product Characteristics (SmPC) for the full therapeutic indication.1
Xolair directly targets and binds to IgE,1–3 preventing histamine release.2,3
Xolair binds to free IgE, preventing it from binding to the FcεRI on mast cells and basophils and results in downregulation of FcεRI on these cells1,3
The exact mechanism of action of Xolair in the treatment of CSU is uncertain, and changes in symptoms are likely due to a combination of mechanisms1,3,4
Watch this short mechanism of action video to understand more how Xolair is used in the treatment of CSU.
VIDEO
CSU, chronic spontaneous urticaria; FcεRI, high-affinity IgE receptor; IgE, immunoglobulin E; SmPC, summary of product characteristics.
References
Xolair® (omalizumab) Summary of Product Characteristics.
Chang TW, et al. J Allergy Clin Immunol 2015;135(2):337–342.
Kaplan AP, et al. Allergy 2017;72(4):519–533.
Kocatürk G, et al. Turkderm-Turk Arch Dermatol Venereol 2018;52:112–119.
UK | March 2025 | FA-11360033
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.
*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.
